Search Results for “H19-423_V1.0 Latest Test Testking 🍀 H19-423_V1.0 Practical Information 📄 H19-423_V1.0 Test Price 🕔 Go to website ☀ www.pdfvce.com ️☀️ open and search for ➠ H19-423_V1.0 🠰 to download for free 🎤H19-423_V1.0 Download Pdf” – Page 38

Diagnosis of urticaria

33.	Schoepke, N., Doumoulakis, G., and Maurer, M.+: Diagnosis of urticaria. In: Godse, K., editor: Urticaria. New Delhi: Jaypee Brothers Medical Publishers (P) Ltd., 2016

bc.33

32.	Maurer, M., Magerl, M., Zuberbier, T., and Weller, K.: Urticaria. In: Kabashima, K., editor: Immunology of the skin. Japan: Springer, 2016

58.	Weller, K., Soost, S., Worm, M., Maurer, M., and Zuberbier, T.: Atopic dermatitis and allergic rhinitis – do co-effects in therapy exist? J. Dtsch. Dermatol. Ges. 2012: 10; 221-239. IF: 1.40

26.	Maurer, M. and Zuberbier, T.: Hypersensitivity vasculitis. In: Akdis, C. A. and Agache, I., editors: Global atlas of allergy. EAACI, 2014

16.	Zuberbier, T. and Maurer, M.: Urticaria: Current opinions about etiology, diagnosis and therapy. Acta Derm. Venereol. 2007: 87; 196-205. IF: 1.93

17.	Metz, M. and Maurer, M.: Mast cells – key effector cells in immune responses. Trends Immunol. 2007: 28; 234-241. IF: 9.48

Effects of topical treatment with the raft modulator miltefosine and clobetasol in cutaneous mastocytosis: a randomized, double-blind, placebo-controlled trial

Hartmann, K.+, Siebenhaar, F., Belloni, B., Brockow, K., Eben, R., Hartmann, B., Ruëff, F., Schoepke, N., Staubach, P., Weber, A., and Maurer, M.: Effects of topical treatment with the raft modulator miltefosine and clobetasol in cutaneous mastocytosis: a randomized double-blind, placebo-controlled trial. Brit. J. Dermatol. 2010: 162; 185-190. IF: 4.35

o.095

Elderly versus younger patients with hereditary angioedema type I/II: patient characteristics and safety analysis from the Icatibant Outcome Survey

359

Bygum, A.+, Caballero, T., Grumach, A. S., Longhurst, H. J., Bouillet, L., Aberer, W., Zanichelli, A., Botha, J., Andresen, I., Maurer, M. for the IOS study group: Elderly versus younger patients with hereditary angioedema type I/II: patient characteristics and safety analysis from the icatibant outcome survey. Clin. Transl. Allergy 2019: 9; 37. IF: 5.13

o.359

128.	Bygum, A., Busse, P., Caballero, T., and Maurer, M.+: Disease severity, activity, impact, and control and how to assess them in patients with hereditary angioedema. Front. Med. 2017: 4; 212. IF: : 2.03

Diagnosis and treatment of urticaria and angioedema: a worldwide perspective

67.

Sánchez-Borges, M., Asero, R., Ansotegui, I. J., Baiardini, I., Bernstein, J. A., Canonica, G. W., Gower, R., Kahn, D. A., Kaplan, A. P., Katelaris, C., Maurer, M., Sim Park, H., Potter, P., Saini, S., Tassinari, P., Tedeschi, A., Min Ye, Y., Zuberbier, T., and the WAO Scientific and Clinical Issues Council: Diagnosis and treatment of urticaria and angioedema: a worldwide perspective. World Allergy Organ. J. 2012: 5; 125-147. IF: N/A

r.067

Results